Related Experiment Video

Updated: Sep 23, 2025

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

16.8K

DMDRMR promotes angiogenesis via antagonizing DAB2IP in clear cell renal cell carcinoma

Yumeng Zhu1,2, Xiaojun Liu1,2, Yang Wang3

  • 1School of Biomedical Engineering (Suzhou), Division of Life Sciences and Medicine, University of Science and Technology of China, 230026, Hefei, China.

Cell Death & Disease
|May 13, 2022
PubMed

Insights

A novel long non-coding RNA, DMDRMR, promotes angiogenesis and sunitinib resistance in clear cell renal cell carcinoma (ccRCC) by regulating the miR-378a-5p/DAB2IP axis. This finding offers a potential new therapeutic target for ccRCC treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Clear cell renal cell carcinoma (ccRCC) exhibits high angiogenesis, often treated with VEGFA/VEGFR pathway inhibitors.
  • Tumor resistance to targeted therapies remains a significant clinical challenge in ccRCC.
  • Understanding the mechanisms driving angiogenesis is crucial for developing effective ccRCC treatments.

Purpose of the Study:

  • To elucidate the molecular mechanisms underlying angiogenesis and targeted therapy resistance in ccRCC.
  • To identify novel regulatory pathways involved in ccRCC pathogenesis.
  • To explore potential therapeutic targets for ccRCC.

Main Methods:

  • Investigated the role of long non-coding RNA DMDRMR in ccRCC.
  • Analyzed the interaction between DMDRMR, miR-378a-5p, EZH2, SMURF1, and DAB2IP.
  • Assessed the impact of this axis on VEGFA/VEGFR2 signaling, angiogenesis, and sunitinib resistance in ccRCC cells.
  • Correlated DMDRMR expression with ccRCC patient prognosis.

Main Results:

  • Demonstrated that DMDRMR acts as a competing endogenous RNA (ceRNA) sponge for miR-378a-5p.
  • Showed that DMDRMR upregulates EZH2 and SMURF1, leading to repression and degradation of DAB2IP.
  • Confirmed that this axis activates VEGFA/VEGFR2 signaling, promoting angiogenesis and sunitinib resistance in ccRCC.
  • Found a clinical relevance of the DMDRMR/miR-378a-5p/DAB2IP axis to ccRCC pathogenesis and patient prognosis.

Conclusions:

  • The DMDRMR/miR-378a-5p/DAB2IP axis promotes angiogenesis and sunitinib resistance in ccRCC.
  • This regulatory axis is clinically relevant for ccRCC pathogenesis and prognosis.
  • The DMDRMR/miR-378a-5p/DAB2IP axis represents a potential novel target for the diagnosis or combination therapy of ccRCC patients.

More Related Videos

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane05:36

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane

Published on: February 8, 2020

9.1K
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.7K

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.0K